Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Jodi Segal-Lankry who wrote (32)	2/22/1998 12:08:00 PM
From: Thomas Kirwin	Respond to of 422

Stock Repurchase Program Status Jodi, My initial research reveals that there has been no stock purchases made by Immucor since the repurchase program was announced on 06/02/97. In fact, the number of average outstanding shares has increased ever so slightly with each earnings report from the 8.1 million mentioned in the original release to ~8.5 million as of the last report. This could be the result of in the money options or incentives paid to key management. Remember this program is completely voluntary with no repurchase minimum stated and can be terminated at any time. Immucor Authorizes Stock Repurchase Program PR Newswire, Monday, June 02, 1997 at 08:28 NORCROSS, Ga., June 2 /PRNewswire/ -- Immucor, Inc. (NASDAQ:BLUD), maker of blood bank reagent systems and related products, announced today it has authorized a program to repurchase up to ten percent (10%) of its common stock in the open market. The Company currently has 8.1 million common shares outstanding. "We believe market conditions have provided us with an opportunity to enhance shareholder value by purchasing stock at attractive prices," said Edward L. Gallup, president of Immucor. Mr. Gallup also noted that the Company is not committed to purchase any minimum number of shares, and the Company may terminate the repurchase program at any time. Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used primarily by hospitals and donor centers in a number of tests performed to detect and identify certain properties of the cell and serum components of blood prior to transfusion. SOURCE Immucor, Inc. 06/02/97 CONTACT: Richard J. Still or Connie Vinson, Corporate Communications, Immucor, Inc., 770-441-2051/ Regards, Tom

To: Jodi Segal-Lankry who wrote (32)	7/9/1998 12:09:00 AM
From: Thomas Kirwin	Respond to of 422

Congratulations & Random Thoughts Re-post from AOL Immucor Message Boards...... Subject: Re: Share Price & Sales Projections Date: Wed, Jul 8, 1998 18:55 EDT From: BSGPKG Message-id: <1998070822555600.SAA11372@ladder03.news.aol.com> First I would like to congratulate Ed Gallup and all the long term shareholders of Immucor who have waited for this approval. I would like to add my 2 cents about the future stock price. While I do not have a number the stock will hit, Immucor has had to know this approval has been coming for some time and has had ample time to prepare. I think 75 units the first year is too low a projection. I don't have a crystal ball but twice that number would not surprise me. If, that is, Immucor exists at all by the end of the year. I also agree this is a great buying opportunity. Best of luck to every one of you guys. Bob

To: Jodi Segal-Lankry who wrote (32)	10/2/1999 1:46:00 PM
From: Thomas Kirwin	Respond to of 422

Update - Instrument Sales & e-Commerce Initiative My limited sources report that Immucor Rock & Roll Instrument Road Shows continue to result in closed deals, serious interest and proposal requests. Translation - Instrument sales are doing very well. IMHO - My short term price target of $21-$22 would have been attained or even surpassed if only Immucor conducted Wall Street Investment Tours and got their story out. Recently, I requested info regarding Ready-ID.com and was very pleased with the response. It seems that the US Market is willing to pony up as much as $40 per antibody id inquiry. Of course the rest of the world may not be so inclined. :-) Remember the US represents a major market in and of itself! Note - Over 200,000,000 blood screens and antibody identifications are performed each year. It's a fact that Ready-Id.com will save users time and money. It virtually eliminates the need for a well paid antibody id specialist. This service will be huge as it includes an education suite and reference service generating additional revenue. IMHO margins will very generous! The e-Commerce and connectivity initiative is on track and going very well. Best O'Luck, Tom